Efficacy of extract in amyloid PET-positive patients with mild cognitive impairment.

BACKGROUND

Mild cognitive impairment (MCI) with amyloid PET positivity represents a prodromal stage of Alzheimer's disease (AD), yet no disease-modifying therapies are currently approved. , traditionally used in East Asian and European ethnomedicine as an oral decoction or standardized extract to support memory and cognitive function, is commonly utilized, however, its efficacy as monotherapy in biomarker-confirmed MCI remains uncertain. Aβ oligomers, produced by abnormal cleavage of amyloid precursor protein, disrupt synaptic function and contribute to cognitive decline.

OBJECTIVE

This study evaluated whether alone, without adjunctive anti-dementia medication, could provide clinical and biomarker benefits in amyloid PET-positive MCI patients. Plasma MDS-Oaβ (Multimer Detection System-Oligomeric Aβ), a dynamic biomarker reflecting Aβ oligomerization tendency, was used to explore mechanistic relevance.

METHODS

In this retrospective cohort study, 64 amyloid PET-positive MCI patients were followed for 12 months. Participants received either oral monotherapy (240 mg/day,  = 42) or standard cognitive enhancers ( = 22). Clinical outcomes included the Korean version of the Mini-Mental State Examination (K-MMSE), Clinical Dementia Rating-Sum of Boxes (CDR-SB), Korean Instrumental Activities of Daily Living (K-IADL), and Neuropsychiatric Inventory (NPI). Plasma MDS-Oaβ levels were assessed at baseline and at 12 months.

RESULTS

At 12 months, the Ginkgo group showed significantly higher responder rates (100% vs. 59.1%,  < 0.001), no conversion to AD dementia (0% vs. 13.6%,  = 0.037), and greater improvement in K-MMSE and K-IADL scores. MDS-Oaβ levels decreased significantly in the Ginkgo group ( < 0.001) but not in the control group. No significant between-group differences were observed in CDR-SB or NPI scores.

CONCLUSION

monotherapy was associated with preserved cognition, improved daily functioning, and reduced plasma Aβ oligomerization in amyloid PET-positive MCI patients. These findings suggest potential disease-modifying effects and warrant further validation in prospective, biomarker-based clinical trials.